- Home
- LGHL vs WINT Comparison
LGHL vs WINT Comparison
Compare LGHL & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGHL
- WINT
- Stock Information
- Founded
- LGHL 2015
- WINT 1992
- Country
- LGHL Singapore
- WINT United States
- Employees
- LGHL N/A
- WINT N/A
- Industry
- LGHL Investment Bankers/Brokers/Service
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGHL Finance
- WINT Health Care
- Exchange
- LGHL Nasdaq
- WINT Nasdaq
- Market Cap
- LGHL 1.8M
- WINT 2.2M
- IPO Year
- LGHL N/A
- WINT 1995
- Fundamental
- Price
- LGHL $2.29
- WINT $0.55
- Analyst Decision
- LGHL
- WINT Hold
- Analyst Count
- LGHL 0
- WINT 1
- Target Price
- LGHL N/A
- WINT $350.00
- AVG Volume (30 Days)
- LGHL 307.2K
- WINT 18.3M
- Earning Date
- LGHL 08-19-2025
- WINT 08-18-2025
- Dividend Yield
- LGHL N/A
- WINT N/A
- EPS Growth
- LGHL N/A
- WINT N/A
- EPS
- LGHL N/A
- WINT N/A
- Revenue
- LGHL N/A
- WINT N/A
- Revenue This Year
- LGHL N/A
- WINT N/A
- Revenue Next Year
- LGHL N/A
- WINT N/A
- P/E Ratio
- LGHL N/A
- WINT N/A
- Revenue Growth
- LGHL N/A
- WINT N/A
- 52 Week Low
- LGHL $2.13
- WINT $0.36
- 52 Week High
- LGHL $20.86
- WINT $663.44
- Technical
- Relative Strength Index (RSI)
- LGHL 39.44
- WINT 38.51
- Support Level
- LGHL $2.18
- WINT $0.50
- Resistance Level
- LGHL $2.48
- WINT $1.02
- Average True Range (ATR)
- LGHL 0.31
- WINT 0.10
- MACD
- LGHL -0.08
- WINT -0.04
- Stochastic Oscillator
- LGHL 10.60
- WINT 6.74
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.